• Direct-sales environment is evolving as younger generations explore opportunity
• Changing consumer behaviors, a tough regulatory environment and lingering supply chain struggles are industry challenges
• SHRG’s primary growth strategy is built on focused innovation and creativity positioned to capture profitable market share

The beginning of a new year is an ideal time to reflect on what the direct-sales industry may look like this year, and companies such as Sharing Services Global (OTCQB: SHRG) are likely to benefit as the space appears set to see significant growth. “To say direct selling is in a time of transition would be an understatement,” said a recent Direct Selling News article (https://nnw.fm/W6pFi). (https://ibn.fm/peKaf). “The environment is evolving as younger generations explore the opportunity. And the post-pandemic trends of quiet quitting and the desire for more workplace flexibility continue to shape where, how and why people of all ages choose to earn a living. Everyone working in the industry is aware of the decisions, pivots and pain points we have ahead of us as executives, as companies and as a channel.” The article explained that Direct Selling News reached out to 75 C-level executives representing a combined $43 billion in revenue to gather feedback regarding the challenges and opportunities facing the channel. “The topics most often mentioned should come as no surprise,” the article observed. “Concerns like changing consumer behaviors and a tough regulatory environment as well as lingering supply chain struggles, Amazon and eCommerce strategies and field fatigue were mentioned often. Mergers, acquisitions and consolidations also continue to be a popular topic of conversation.” Staying on top of the trends and looking for solutions to the challenges in the direct-selling space is a priorty for Sharing Services, a company dedicated to building shareholder value by developing or acquiring businesses, products and technologies in the direct-selling industry as well as other industries that augment its product and services portfolio, business competencies, and geographic reach (https://nnw.fm/CDMbO). (https://ibn.fm/qwyNK). “Our primary growth strategy is built on focused innovation and creativity positioned to capture profitable market share of diverse business models,” the company website declares. The company operates with a mission designed to “increase shareholder value by adhering to standards of excellence that optimize the value of the people involved, supply chain, and channel of distribution, achieving optimal customer satisfaction through every subsidiary and partnership interest.” SHRG currently has some form of controlling interest in My Travel Ventures(TM), which makes it easy to plan, book and save on travel adventures near and far; MojiLife, which offers a flagship product to scent homes and vehicles that features the latest in innovative technology and design (https://nnw.fm/ZvYVV); (https://ibn.fm/mSu9d); and the Happy Co., which offers functional beverages, capsules, patches, and creams that elevate mood, boost energy, reduce stress, enhance sleep, increase muscles, minimize fat, tighten skin, and make users look, feel and perform like a younger person (https://ibn.fm/XyAbN). The company’s combined platform currently leverages the capabilities and expertise of various companies that market and sell products direct to the consumer through independent contractors. For more information, visit the company’s websites at www.SHRGInc.com, www.MyTravelventures.com and www.TheHappyCo.com. NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• SideChannel is on a mission to make cybersecurity simple and accessible, mainly targeting small and mid-sized organizations which often fall victim to hackers given their insufficient budgets to invest in an on-site Chief Information Security Officer (“CISO”)
• With hacking and ransomware attacks on the rise, crypto operations, as well as other small and mid-sized organizations, are at risk of falling victim, resulting in a disruption and potentially damaging their operations
• While code audits are still essential, SideChannel’s unique approach to the problem (creating top-tier cybersecurity programs) guarantees both asset and data protection for these enterprises

Within the first three months of 2022, hackers had stolen over $1.3 billion from exchanges, platforms, and private entities, with the victims disproportionately in Decentralized Finance (“DeFi”) and crypto. In 2021, over $3.2 billion worth of cryptocurrency was stolen, and it is projected that the cybersecurity risks to crypto operations will only increase as time progresses (https://ibn.fm/ef8ga). SideChannel (OTCQB: SDCH), a company on a mission to make cybersecurity simple and accessible, is looking to remedy the situation, mainly by targeting small and mid-sized organizations which often fall victim to hackers given their insufficient budgets to invest in the expertise of an experienced Chief Information Security Officer (“CISO”). By matching companies with an expert virtual CISO (“vCISO”), SideChannel helps them to improve their cybersecurity and move their mission forward. Furthermore, it enables these enterprises to assess cyber risk and ensure cybersecurity compliance without spending sums that could potentially jeopardize their financial assets (https://ibn.fm/BXyqb). SideChannel’s tailor-made services for crypto and digital asset supply chain cut across exchanges, wallets, mining operations, construction, and power, with the guarantee of defending current security investments while integrating new tools and consumer data protection without disruption. The company also promises a proactive defense that stops threats before they get to data while at the same time reducing security costs by aligning security strategy to overall business goals. This approach has allowed SideChannel’s operations to scale its operations, covering crypto trading platforms, producers and brokers, hedge funds, mining operations, exchanges, and identities, with a huge market opportunity that continues to grow with every passing day. With hacking and ransomware attacks on the rise, small and mid-sized organizations and crypto exchanges risk falling victim and disrupting their operations, which is costly and potentially damaging to their operations. Threats that include, but are not limited to, commodity exploits, distributed denial of service attacks (“DDoS”), and code corruption have the potential to halt entire business operations, especially in the crypto and digital asset sectors (https://ibn.fm/u4b4f). However, SideChannel seeks to make solutions more accessible and affordable, ultimately becoming an integral partner to small and mid-sized enterprises in this sector. SideChannel’s management acknowledges that code audits can help with reducing the risk of a successful hack. However, with Chainanalysis estimating that nearly 30% of code exploits occurred on platforms audited within the past year, coupled with a surprising 73% of flash loan attacks, there is a need for a more robust and practical approach to maintaining the integrity of these systems. This highlights SideChannel’s unique approach to the problem- creating top-tier cybersecurity programs for small businesses to help them protect their assets and data. “As companies invest more in cyber resilience, criminals are finding sophisticated pathways around their defenses, meaning the most dangerous weaknesses are the invisible ones,” noted Dustin Warren, the senior security researcher at cybersecurity company, SpyCloud (https://ibn.fm/E9BC8). So far, SideChannel has attracted over 20 virtual CISOs to serve across industries, including fintech, biotech, healthcare, manufacturing, legal, defense, crypto, and technology services. With the global cybersecurity market projected to grow from an estimated $173.5 billion in 2022 to $266.2 billion by 2027, the company is readying itself to capitalize on this growth and is on track to do so (https://ibn.fm/LxfM2). By supporting the crypto and digital asset supply chain to include wallets, identities, mining operations, exchanges, power, and identities, SideChannel is aiding with the proliferation of crypto, and the growth of the sector, which is estimated to post a CAGR of 12.2% from 2022 to 2030. This has facilitated its growth thus far, having posted a 71% year-over-year growth (https://ibn.fm/AbbDN), which Brian Haugli, its CEO, termed as a “demonstration of our [the company’s] continued strength and position in the market across both product and service delivery.” For more information, visit the company’s website at www.SideChannel.com. NOTE TO INVESTORS: The latest news and updates relating to SDCH are available in the company’s newsroom at https://ibn.fm/SDCH

• Cerberus believes successful cybersecurity must be woven into an organization’s fabric, transforming its culture
• While cybersecurity has become a well-known topic, surprisingly few companies are doing anything about it
• Every 11 seconds, someone is targeted or hacked, and the weakest link inside a company is people who aren’t prepared, says CISO CEO

The idea that “cybersecurity is a culture, not a product” has never been more relevant or profound, says podcast host Ted Jenkin, who chatted with Cerberus Cyber Sentinel (NASDAQ: CISO) CEO David Jemmett during a recent episode of “The Shrimp Tank” (https://ibn.fm/o4CTg). Cerberus has trademarked that phrase and operates on the principle that successful cybersecurity is more than amassing a list of vendors and varied technologies; it must be woven into the fabric of an organization, encompassing and transforming that organization’s culture.

“When I saw their slogan that cybersecurity is a culture not a product, I think there probably couldn’t have been a more opportune time to interview David today because that really encapsulates what is happening today in America,” said Jenkin. “Whether you just have a few PCs in your house, or you’ve got a company of thousands of employees, today the question is: Are you more susceptible to a physical attack, or are you more susceptible to a cyberattack? And we’re seeing [cyberattacks] happen every single day.”

During the interview, Jemmett noted that, although cybersecurity is often discussed and has become a well-known subject in today’s business world, surprisingly few companies are doing enough about this very real threat.  “A lot of folks are not addressing [cybersecurity]… They don’t want to know what they don’t know because they’re going to have to fix it, which costs money,” Jemmett said. “Cybersecurity is an actual concern that people should be aware of, and training and understanding what really happens is important.”

Jemmett also pointed out that “every 11 seconds, someone is being targeted or hacked, and the weakest link inside a company is the people not being prepared. The reason we trademarked ‘Cybersecurity is a culture, not a product’ is because it’s from the top down. If leadership doesn’t understand, it becomes a black hole. How can you address something you’re not understanding?” This is a key point, given that many organizations have worked to educate their C-suites about the importance of cybersecurity but have not helped them deepen their technical knowledge.

As an industry thought leader, David Jemmett wants leadership teams to understand more than just the importance of cybersecurity. He knows that C-suites and boards need to be cyber-literate enough to determine how things work and which technical and process investments matter most and in what order. Otherwise, it’s easy to simply invest the latest technology and assume their problems are solved.

Additionally, Jemmett observed that traditional IT is different than cybersecurity. “IT puts systems together and tries to secure it after they’ve designed it. We think like hackers, with security by design… [Companies] should start any kind of application or implementation of services by understanding how to secure it first, but a lot of people don’t have that understanding. It pays to go get someone to help them through that process, but make sure they’re professionals. If you get in a car accident and go to the emergency room, you don’t want a dermatologist or general practitioner working on you; you want someone who has years of experience.”

Cerberus brings many years of experience to the table. The company’s leadership team has decades of success in a range of sectors, including executive management and technology experience in cybersecurity consulting services; securely engineering, building, revamping and managing global networks and data centers; cybersecurity application and implementation across military, financial services and professional services organizations; cyber force development; cyber defense operations; and cybersecurity advisement.

The company is widely recognized as a managed cybersecurity and compliance provider. Today, Cerberus is expanding by acquiring world-class cybersecurity, secured managed services and compliance companies with top-tier talent that utilizes the latest technology to create innovative solutions to protect the most demanding businesses and government organizations against continuing and emerging security threats and compliance obligations.

For more information, visit the company’s website at www.CerberusSentinel.com.

NOTE TO INVESTORS: The latest news and updates relating to CISO are available in the company’s newsroom at https://ibn.fm/CISO

• Silo Pharma recently provided an update on an ongoing study delving into the potential use of SPU-21 joint homing peptides as an alternative treatment for rheumatoid arthritis
• The study, which is being carried out in conjunction with the University of Maryland, Baltimore, has resulted in positive initial results
• Since its founding, Silo Pharma has rapidly gained a reputation for its innovative approach towards seeking solutions to address a variety of underserved medical conditions

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused around merging traditional therapeutics with psychedelic research, recently revealed the positive interim data from its dose optimization study of SPU-21 joint homing peptides for subcutaneous administration of anti-arthritic agents. The results come after the biopharmaceutical company initiated a pilot study on its novel joint homing peptides targeting rheumatoid arthritis in late November, specifically looking into the binding affinity of the peptide in healthy human and RA synovial tissue.

At the time, Eric Weisblum, Chief Executive Officer of Silo Pharma explained the rationale underpinning the study, “SPU-21 was shown to inhibit arthritic progression in a preclinical animal model, so we are proceeding to advance our research into human synovial tissue, where we will first assess binding affinity.  Positive data from this important study could support further research into the interaction of our joint homing peptide as a potential therapy for autoimmune disorders such as rheumatoid arthritis and inflammation.”

Rheumatoid arthritis is among the most common autoimmune diseases in the U.S., affecting approximately 1.5 Americans.  A 2022 report published by Precedence Research revealed that the global rheumatoid arthritis drugs market was expected to reach $70 billion by 2030, growing at a compound annual growth rate of 1.7% (https://ibn.fm/S8bqi).

Although historically treated using DMARDs (disease-modifying antirheumatic drugs) or steroids, Silo Pharma has sought to advance the use of liposomal homing peptides as an alternative treatment for rheumatoid arthritis, with a positive test result from the ongoing study potentially acting as justification for further investigation.

Silo Pharma provided an update on the ongoing study as of December 30, 2022. During the study, tests were conducted to evaluate the disease-suppressive effects of an SPU-21 peptide-guided anti-arthritis drug versus the drug alone. The drug used in the study was dexamethasone (“DEX”), a corticosteroid used for its anti-inflammatory and immunosuppressant effects. Earlier results of the same study successfully demonstrated that the subcutaneous (“SC”) route of liposomal administration (small needle injection into shallow soft tissue just under the layer of skin) was-suited for use in targeted drug delivery of anti-arthritic agents (https://ibn.fm/h5fq6).

“We believe that the positive results of these latest tests show that our peptide with DEX given subcutaneously was effective in controlling arthritis progression.  The effect of lipo-DEX was superior to that of DEX alone when both were administered via the SC route,” elaborated Eric Weisblum. “Since patients widely prefer SC administration over intravenous (‘IV’) infusion for multiple reasons, we believe the superiority and practicality of our liposomal joint homing peptide bode well for broad market potential. Meanwhile, we continue to explore other novel therapeutics for optimal pairing with SPU-21, targeting rheumatoid arthritis as our initial indication.”

Originally founded in 2010, Silo Pharma has rapidly earned a reputation in recent years for its ground-breaking research into conditions such as post-traumatic stress disorder (“PTSD”), fibromyalgia, Alzheimer’s disease, Parkinson’s disease, and other rare neurological disorders. Whilst promising in nature, the company’s study into joint-homing peptides, which it is carrying out in conjunction with the University of Maryland, Baltimore, is just one of a multitude of promising initiatives Silo Pharma is currently pursuing. Other projects also include a study focused around assessing the effect of psilocybin on inflammation being carried out with the University of California, San Francisco (“UCSF”) as well as an agreement with Columbia University, with both entities jointly exploring the use of prophylactic treatment for stress-induced disorders and PTSD (https://ibn.fm/YWacO).

For more information, visit the company’s website at www.SiloPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO

• Energy costs are surging across America, driven by overreliance on natural gas; this dominant fuel source for both home heating and electricity generation has soared in price
• More and more states across the country are starting to push for renewable energy adoption as benefits, both environmental and economic, are becoming apparent
• As the country’s unsustainable dependence on gas brings another hit to consumers’ budget, companies like GeoSolar works to offer a better path forward with solutions designed to protect both the environment and consumers’ wallets

Americans are looking to take their green effort to a new level with sustainable living as fossil fuel-induced climate change has worsened the risk of extreme weather events, increasing them in frequency, intensity, and scale. Coupled with energy price increases due to heightened international uncertainties, it highlights the need for a shift from our reliance on energy from fossil fuels. In an environment like this, companies like GeoSolar Technologies (“GST”), a Colorado-based climate technology Company, stand to benefit as rising awareness of climate change is accompanied by the increasing understanding that overreliance on fossil fuels can have a detrimental economic impact on consumers through high energy costs. Energy prices are soaring, and many American households feel the pinch as they struggle to cope with rising energy bills (https://ibn.fm/awZQo). In some parts of the country, wholesale power prices soared more than 6,000% amid the height of the recent cold wave, likely bringing considerably higher heating costs as the natural gas price spike gets passed on to consumers. This kind of climate events could become more common as climate change causes more extreme weather. Currently, almost three-quarters of buildings in the U.S. use fossil fuels for heating and other everyday living needs, thus creating 10% of the country’s carbon pollution every year. Since half of the new homes are built with fossil fuel heating or appliances, carbon pollution could be locked in for decades (https://ibn.fm/rCvrC). In addition to being a mounting threat to the natural environment and societies, affecting our well-being and a healthy planet, this also means an overreliance on fossil fuels–a commodity with escalating prices. But there could be a better way forward. It is becoming increasingly clear that green energy can help Americans save money and reduce carbon pollution. For example, electrification means transitioning from using fossil fuels to using clean energy to run home appliances for existing and new homes alike. Renewables such as solar panels with battery storage can help American consumers to take counteraction against soaring energy bills (https://ibn.fm/zhK82). To retrofit existing homes, electrification means to switch to electric devices that can considerably reduce or even eliminate carbon pollution, and for new ones, it means ensuring a construction that is electric-ready. More states are taking legislative steps to promote renewable energy in their bid to decarbonize buildings as part of comprehensive legislation that considers impacts on energy efficiency, the electrical grid, and natural gas infrastructure. For example, Washington State passed a new energy regulation that mandates heat pumps for most new buildings beginning in July. Claimed by many to be the most robust, climate-friendly state building energy code for new construction, it requires heat pumps for both space and water heating with the goal of reducing the use of fossil fuels and the greenhouse gas emissions that result from burning them (https://ibn.fm/KxNdU). Other parts of the country – from California, Maryland, Colorado, Illinois, Montgomery County and New York to Los Angeles, Chicago, Honolulu, Boston – are hopping on the green bandwagon as the benefits of action become harder to ignore. As a Colorado-based climate technology Company, GeoSolar appears well-positioned to capitalize on the growing momentum of green energy across the country amid this push for green energy alternatives. With its SmartGreen™ holistic renewable energy systems that include rooftop photovoltaic solar panels and geothermal ground loops, GeoSolar works to help consumers capitalize on the power of the sun and earth to provide heating, air conditioning, and electricity. This innovative solution is designed to offer a comprehensive energy transformation, adaptable to almost any home type, including new construction and existing buildings. The SmartGreen™ Home system can produce all the energy a home needs in addition to providing an electric vehicle charging station. For more information, visit the company’s website at www.GeoSolarPlus.com. NOTE TO INVESTORS: The latest news and updates relating to GeoSolar Technologies are available in the company’s newsroom at https://ibn.fm/GST

• The growing perception is that cannabis companies investing in real estate raise the value of the area in which they invest
• A 2020 study conducted in states where medicinal and recreational cannabis is legal found that 35-36% of respondents saw an increase in demand for warehouses, 23% for storefronts, and up to 28% for land
• The global legal cannabis market was valued at $17.8 billion in 2021 and is expected to reach $134.4 billion by 2030
• REZYFi is leveraging its corporate strengths through two wholly-owned subsidiaries – REZYFi Lending and ResMac Inc. – offering a diversified approach to cannabis and real estate financing that traditional banks are reticent to offer

Cannabis and real estate have a unique relationship. The growing perception on the market is that cannabis companies investing in real estate raise the value of the area they invest in. Three strong arguments support the perception – abandoned buildings are gaining new life when rehabilitated by cannabis businesses, entrepreneurs are investing in the cannabis market as an asset that does not depreciate over time, and new jobs are increasing residential home sales. In a 2020 study conducted in states where cannabis for medicinal and recreational purposes is legal, 35 to 36% of respondents noted an increase in demand for warehouses, 23% for storefronts, and up to 28% for land (https://ibn.fm/IbY2Q). At the forefront of cannabis and real estate is REZYFi, a growth mortgage origination and specialized financing company in the United States. REZYFi originates, structures, and invests in first mortgage loans and alternative structured financing secured by commercial real estate properties. The company’s target market includes licensed and permitted cannabis companies, owners of real estate who lease to cannabis companies, and companies and individual homeowners seeking a variety of real estate-related first and additional mortgage-based financing. The global legal cannabis market was valued at $17.8 billion in 2021 and is expected to grow to $134.4 billion by 2030, growing at a CAGR of 25.3%. The market is expected to grow due to the increase in the legalization of cannabis and the acceptance of its use in the medical industry. The FDA has issued several guidelines, and new policies are underway to regulate the use of cannabis – ultimately driving investment in the cannabis industry (https://ibn.fm/V2aoS). REZYFi operates through two wholly-owned subsidiaries and is positioned as one of the first cannabis mortgage bankers in the United States, an area most traditional banks are hesitant to serve. REZYFi Lending primarily addresses emerging real estate-related financing opportunities, leveraging a wide network to offer options such as 15- and 30-year fixed-rate loans, FHA loans, VA loans, reverse mortgages, jumbo loans, and adjustable-rate mortgages. ResMac Inc. has been operating for 13 years and is the company’s traditional mortgage origination, correspondent, and servicing operation. REZYFi expects to accumulate $285 million in retail origination in 2023, alongside $250 million in wholesale origination during the same period. REZYFi is using a diversified approach to the real estate lending sector to capitalize on growth in multiple verticals in the years to come. The company’s experience, network of independent brokers, and proprietary technology allow it to leverage the industry and offer a wide range of real estate and financing options that were not readily available. As of December 2022, the company is licensed in 36 states and plans on expanding to all states in the future. For more information, visit the company’s website at www.REZYFi.com. NOTE TO INVESTORS: The latest news and updates relating to REZYFi are available in the company’s newsroom at https://ibn.fm/REZY

• Correlate Infrastructure Partners Inc. is a distributed energy solutions company drawing on tech-enabled development, finance, and fulfillment resources, to support businesses that develop and rent out commercial building properties
• Commercial real estate industry businesses served by CIPI are among a large field of corporations working to improve their environmental, social and governance (“ESG”) profiles in order to appeal to climate-conscious investors
• ESG-conscious investment rose to a record $69.2 billion in 2021 and continues to weather “anti-woke” pushback efforts that have become more pronounced in recent months
• Multinational investment bank JPMorgan Chase provided a good of ongoing climate consciousness when it announced 2030 carbon-reduction targets for the oil and gas, electric power, and auto manufacturing sectors last year, and added similar goals for the iron and steel, cement, and aviation sectors this month

Distributed energy solutions company Correlate Infrastructure Partners (OTCQB: CIPI) is helping clients do more to improve their environmental, social and governance (“ESG”) profiles as investors show a growing interest generally in backing such efforts. In 2021, shareholders dedicated a record $69.2 billion to ESG-weighted funds (https://ibn.fm/1wYJL).

In addition to the U.S., European investors have continued to flex ESG muscle to put expanding pressures on industry to do more and do it better in regard to climate-friendly activity (https://ibn.fm/XebXi). In 2021, multinational investment bank and financial services holding company JPMorgan Chase announced steps to align its financing activities with climate goals of the 2015 Paris Agreement brokered by the United Nations to reduce carbon pollutants considered responsible for accelerating climate change (https://ibn.fm/135QX).

The investment bank announced this month that it has expanded its goals to reduce emissions by adding targets for the iron and steel, cement and aviation sectors to its 2030 prospects for oil and gas, electric power and auto manufacturing (https://ibn.fm/ogMXZ).

Chase envisions a 31 percent reduction in carbon intensity for the iron and steel sector, a 29 percent reduction for the cement sector and a 36 percent reduction for the aviation sector within the next seven years, according to the statement.

Correlate Infrastructure Partners’ distributed energy solutions include current energy use analysis, recommendations for optimization, and advisement on access to financial resources pegged to help reduce climate impacts for the company’s clients, making potential changes more affordable.

The company recently reported on one of its more significant contracts involving one of the largest behind-the-meter solar installations in the United States — a 3.8-megawatt project at the Pennsylvania headquarters of global stored energy solutions leader EnerSys (https://ibn.fm/hfbLE).

“We are exploring and implementing opportunities to increase our renewable energy usage across our operations,” the first EnerSys Task Force on Climate-related Financial Disclosures (“TCFD”) report stated last month (https://ibn.fm/6d5LT), supplemented by President & CEO David M. Shaffer’s statement that “by identifying important climate-related risks that will impact EnerSys, we can increase our focus on key preparation and mitigation strategies … while also providing valuable information to investors and other stakeholders.”

Laws passed during the past year in the United States, such as the Inflation Reduction Act (“IRA”), have further incentivized companies to explore their options for improving their ESG profiles. The IRA dedicated $370 billion in federal funds to decarbonization efforts, providing companies such as Correlate Infrastructure Partners with greater resources to tap in serving their clients.

For more information, visit the company’s website at www.CorrelateInfra.com, including the following:

• Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income: www.CorrelateInfra.com/our-process
• Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals: www.CorrelateInfra.com/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

• Lexaria has announced patent #3,093,414, its first patent in Canada, its 28th granted patent worldwide, and the first patent from its sixth patent family
• This patent joins the ranks of previously issued patents in Australia, India, Japan, and the EU, even as similar patent applications for skin-based delivery of patented DehydraTECH formulations remain pending in many countries
• In Lexaria’s 2018 study, DehydraTECH-processed CBD demonstrated almost a 1,900% increase in CBD permeability through human skin compared to a control formulation that was devoid of any commercial penetration enhancers
• This patent inches Lexaria closer to taking advantage of the cosmeceuticals market, projected to hit $95.95 billion by 2030, and the global skincare market that is estimated to post a CAGR of 4.6% over the forecast period (2021-2030)

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has announced its 28th granted patent worldwide and the first granted patent from its sixth patent family, titled “Transdermal And/Or Dermal Delivery Of Lipophilic Active Agents.” The Canadian patent #3,093,414 is for improved compositions and methods for transdermal and dermal delivery of cannabinoids, including cannabidiol (“CBD”) and tetrahydrocannabinol (“THC”), all established on the company’s patented DehydraTECH technology (https://ibn.fm/YTQrC). This patent comes three months after Lexaria was granted its 27th worldwide patent in Mexico and just eight months since it was awarded its 25th patent in the United States for “Compositions and Methods For Enhanced Delivery of Antiviral Agents.”  It joins the ranks of previously issued patents in Australia, India, Japan, and the EU, even as similar patent applications for skin-based delivery of DehydraTECH formulations remain pending in many other countries. “This will be our 25th patent granted worldwide and another validation of the versatility of our DehydraTECH drug delivery technology,” noted Chris Bunka, Lexaria’s CEO, during the announcement of the company’s first-ever patent for the use of DehydraTECH technology in the enhanced delivery of antiviral drugs (https://ibn.fm/x723X). In Lexaria’s 2018 study, DehydraTECH-CBD demonstrated almost a 1,900% increase in CBD permeability through human skin compared to a control formulation that was devoid of any commercial penetration enhancements. When pitted against the best-performing commercial penetration enhancer, DehydraTECH-CBD still proceeded to be 225% more effective at penetration through the skin, making it the fastest for absorption into the epidermis, dermis, and through the skin. The cosmeceuticals market is projected to hit $95.75 billion by 2030, up from $45.56 billion in 2021. In addition, the global skincare market is estimated to post a CAGR of 4.6% by 2030, up from $130.5 billion in 2021 (https://ibn.fm/dOo8A). Lexaria recognizes the opportunity therein. This patent inches the company closer to taking advantage of this booming market, allowing it to curve out a niche for itself and establish a market presence, mainly bolstered by its patented DehydraTECH technology. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Report notes that the global direct-selling establishments market is expected to close the year out at a compound annual growth rate (“CAGR”) of 3.8%
• The need for additional income opportunities has been a driving factor in the direct-selling establishments market
• SHRG is committed to stay ahead of marketplace trends, fulfill needs, create sustainable enterprise growth and consistently increase shareholder value

In a market forecast to grow an estimated $20 billion this year alone (https://ibn.fm/tijsB), Sharing Services Global (OTCQB: SHRG) distinguishes itself in the direct-sales space by focusing on a mission to increase shareholder value by adhering to standards of excellence that optimize the value of the people involved, supply chain, and channel of distribution, achieving optimal customer satisfaction through every subsidiary and partnership interest (https://ibn.fm/enZPD). “The global direct-selling establishments market is expected to grow from $449.79 billion in 2021 to $466.73 billion in 2022 at a compound annual growth rate (‘CAGR’) of 3.8%,” reported a recent ResarchandMarketing.com release. “The market is expected to grow to $510.39 billion in 2026 at a compound annual growth rate (‘CAGR’) of 2.3%. “The direct-selling establishments market consists of sales goods and services by entities (organizations, sole traders and partnerships) that are engaged in nonstore retailing of merchandise except e-commerce, mail-order and vending machine sales,” the report continued. “The entities operating in this industry go to the customer’s location rather than the customer coming to them, such as door-to-door sales. The main types of direct-selling establishments are single-level marketing and multilevel marketing. Single-level marketing refers to direct sales carried out by sales associates. The various products include wellness, services, home and family care, personal care, clothing and accessories, leisure and education, and other products having the price range of premium, mid-range, and economy.” The report observes that the need for additional income opportunities has been a driving factor in the direct-selling establishments market. “Direct selling could be a viable income source, even if someone wants to do it part-time,” the report stated. “Direct selling in long-term promotes self-employment and financial independence.” SHRG is committed to stay ahead of marketplace trends, fulfill needs, create sustainable enterprise growth and consistently increase shareholder value. This company vision has led Sharing Services to maximize shareholder value through the acquisition and development of innovative companies, products and technologies in the direct-selling sector and other industries. Currently the company has some form of controlling interest in several enterprises: My Travel Ventures(TM), which makes it easy to plan, book and save on travel adventures near and far; MojiLife, which offers a flagship product to scent homes and vehicles that features the latest in innovative technology and design (https://ibn.fm/1hbyY); and the Happy Co., which offers functional beverages, capsules, patches, and creams that elevate mood, boost energy, reduce stress, enhance sleep, increase muscles, minimize fat, tighten skin, and make users look, feel and perform like a younger person (https://ibn.fm/4xuNN). The company’s combined platform currently leverages the capabilities and expertise of various companies that market and sell products direct to the consumer through independent contractors. For more information, visit the company’s websites at www.SHRGInc.com, www.MyTravelventures.com and www.TheHappyCo.com. NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• Aditxt recently announced the formation of a U.S.-based wholly owned subsidiary, Adimune, Inc., and appointed Joachim-Friedrich Kapp, M.D., Ph.D., a 30-year veteran of the pharmaceutical industry, as its Chairman and CEO
• Dr. Kapp will be tasked with leading and developing the Apoptotic DNA Immunotherapy(TM) (“ADI(TM)”) technology toward clinical trials
• Aditxt also plans to submit a Clinical Trial Application (“CTA”) for immunotherapeutic technology drug candidate ADI(TM)-100, seeking approval for Adimune(TM) to conduct the first-in-human study in psoriasis patients, beginning in the second half of 2023
• ADI(TM) is a nucleic acid-based technology platform that utilizes a novel antigen-specific approach to induce immune tolerance by mimicking the way the body naturally induces tolerance to its own tissues

Aditxt (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, on January 3, 2023 announced the formation of a U.S.-based wholly owned subsidiary, Adimune, Inc. (“Adimune(TM)”). The company also announced the appointment of Dr. Joachim-Friedrich Kapp, M.D., Ph.D., as the CEO of Adimune(TM) and Chairman of the board. A pharmaceutical industry veteran whose career spans 30 years, Dr. Kapp is the former president of the Therapeutics Business Unit at Schering AG, a multinational pharmaceutical company. As CEO of Adimune(TM), Dr. Kapp will be tasked with leading and developing the ADI(TM) immune modulation technology and ADI(TM)-100, Aditxt’s unique and potent antigen-specific immunotherapeutic technology drug candidate, toward clinical trials (https://ibn.fm/LFvTt). “For the past two and a half years, acceleration of the ADI(TM) technology toward clinical trials has been a leading objective of Aditxt, and we now have reached a pivotal milestone by forming a subsidiary with its own dedicated team to advance the commercialization of one of our technologies – ADI(TM),” commented Amro Albanna, Co-Founder, Chairman, and CEO of Aditxt. Short for Apoptotic DNA Immunotherapy(TM), ADI(TM) is a nucleic acid-based technology platform that utilizes a novel antigen-specific approach to induce immune tolerance by mimicking the way the body naturally induces tolerance to its own tissues. The technology, the company believes, selectively suppresses only those immune cells involved in either an autoimmune process or rejection of tissue and organ transplants. “It does so by tapping into the body’s natural process of cell death (apoptosis) to reprogram the immune system to stop unwanted attacks on self or transplanted tissues,” the Adimune website reads (https://ibn.fm/O6PVD). It is this technology platform on which the company based the creation of the ADI(TM)-100 drug candidate, which is set to be evaluated in the planned clinical trials. So far, Aditxt has successfully completed a toxicology study that confirmed the safety profile of ADI(TM)-100. As part of the study, no premature death, no signs of local intolerance, and no test item-related influence on clinical signs, body weight and body weight gains, food consumption, biochemistry, or urinalysis were observed. Additionally, no anti-nuclear antibodies, no macroscopic post-mortem findings, and no changes in histopathology were noted, supporting the safety profile of the drug product (https://ibn.fm/TPQxb). In addition to animal studies in type 1 diabetes, which demonstrated a long-term pronounced treatment effect, the company has also conducted non-clinical studies evaluating ADI(TM)-100 in a stringent model of skin transplantation using genetically mismatched donor and recipient animals, demonstrating a 3x increase in the survival of the skin graft in animals treated with ADI(TM)-100 compared to animals that only received immune suppression drugs. The formulation also prolonged graft life despite the discontinuation of immune suppression after the first five weeks. Moreover, in a short-term induced non-clinical model for psoriasis – a condition caused when the immune system attacks skin cells, triggering chronic production of itchy, inflamed, thick, scaly skin patches – ADI(TM) treatment resulted in down-regulation of pro-inflammatory cytokines and up-regulation of anti-inflammatory cytokines in addition to affecting skin thickness and skin flaking. (all of the parameters assessed during the clinical evaluation of psoriasis skin lesions) (https://ibn.fm/t4vG4). Next, per an October 2022 news release, Aditxt initiated the GMP manufacturing of the drug candidate as a key milestone toward the goal of commencing the first-in-human trials (https://ibn.fm/9eRHh). And to further bolster this goal, the company recently announced its plans to submit within H1, 2023 a CTA for ADI(TM)-100. The CTA application will seek approval for Adimune to conduct the first-in-human study in psoriasis patients, beginning in the second half of 2023. Aditxt also plans to undertake a second study for type 1 diabetes. About Aditxt Aditxt is a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system. Aditxt’s immune monitoring technologies are designed to provide a personalized immune profile. Aditxt’s immune modulating technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases and allergies. For more information, visit the company’s websites at www.Aditxt.com and www.AditxtScore.com. NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX